WNT3 and prostate neoplasm: On the other hand, the overexpression of Wnt ligands has been reported in different cancers—for instance, Wnt1 and Wnt5 in hepatocellular, colon or stomach cancers [58,59,60,61], Wnt5 in lung cancer [62,63,64] and Wnt3 in prostate tumors [65,66,67], as well as Wnt3 and Wnt5 in oral cancer [68,69,70,71].